Insulet Corporation (PODD) – What Are Analysts Saying About This Stock?

Insulet Corporation (NASDAQ:PODD) has been assigned a consensus recommendation of “Hold” from the twenty-six brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and thirteen have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $186.68.

Several research firms have recently weighed in on PODD. Stifel Nicolaus lowered their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. UBS Group reduced their price target on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday, August 6th. Leerink Partners downgraded shares of Insulet from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $247.00 to $145.00 in a research note on Thursday, August 6th. TD Cowen dropped their price objective on shares of Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Insulet during the second quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership grew its position in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Amundi grew its position in Insulet by 14.4% in the 1st quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock valued at $93,781,000 after purchasing an additional 56,225 shares during the period. Renaissance Technologies LLC grew its position in Insulet by 40.5% in the 1st quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock valued at $89,392,000 after purchasing an additional 122,720 shares during the period. Finally, Man Group plc bought a new stake in Insulet during the 2nd quarter valued at $78,746,000.

Insulet Stock Performance

Shares of Insulet stock opened at $149.01 on Friday. The business has a 50-day moving average price of $140.58 and a two-hundred day moving average price of $154.66. Insulet has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.33 billion, a P/E ratio of 27.85, a PEG ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the prior year, the company earned $1.17 EPS. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts anticipate that Insulet will post 6.51 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.